In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood cancer journal (New York) 2024-04, Vol.14 (1), p.65-5, Article 65
Hauptverfasser:	Lund, Thomas, Gundesen, Michael Tveden, Juul Vangsted, Annette, Helleberg, Carsten, Haukås, Einar, Silkjær, Trine, Asmussen, Jon Thor, Manuela Teodorescu, Elena, Amdi Jensen, Bo, Schmidt Slørdahl, Tobias, Nahi, Hareth, Waage, Anders, Abildgaard, Niels, Schjesvold, Fredrik
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/1541/1990/804 692/700/459/1748 Biomedical and Life Sciences Biomedicine Bone and Bones Bone Density Conservation Agents - therapeutic use Bone Diseases - drug therapy Bone Diseases - etiology Bone Diseases - prevention & control Bone Neoplasms Cancer Research Correspondence Diphosphonates - therapeutic use Hematology Humans Medicin och hälsovetenskap Multiple Myeloma - drug therapy Oncology Zoledronic Acid - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!